Sublingual Tirzepatide: What UK Guidance and the Clinical Evidence Say

What the licensed evidence base was built on, and what it wasn't

The clinical case for tirzepatide as a weight-management medicine rests on a large and carefully controlled body of evidence gathered using one specific form: the subcutaneous injection. SURMOUNT-1, the pivotal phase 3 trial published in the New England Journal of Medicine, enrolled 2,539 adults with obesity and followed them for 72 weeks. At the highest dose, participants lost around 20–21% of their body weight on average. That figure is regularly cited (and rightly so) but it applies to subcutaneous tirzepatide titrated under clinical supervision, not to any other preparation.

There are no published randomised controlled trials of sublingual tirzepatide drops or any under-the-tongue formulation. When regulators at the MHRA evaluated the medicine and granted its UK licence, they assessed subcutaneous delivery. The NHS medicines page for tirzepatide describes a once-weekly injection into the abdomen, thigh, or upper arm. That is what the approval covers. A sublingual preparation would require its own independent trial programme, its own safety data, and its own regulatory submission before it could be considered licensed.

Why does delivery route matter so much for a peptide like tirzepatide? Peptide hormones are large molecules. Stomach acid and digestive enzymes break them down rapidly, which is why oral bioavailability for most GLP-1 medicines is extremely low without a specialised absorption enhancer, the kind Novo Nordisk spent years developing for the Wegovy tablet. Under the tongue, absorption depends on the sublingual mucosa, which offers a more direct route into the bloodstream than the gut but still lacks the consistent exposure profile that subcutaneous injection provides. No manufacturer has published data demonstrating adequate or reproducible absorption of tirzepatide via this route, and our page on sublingual tirzepatide tablets goes into more detail on why that matters for anyone weighing up this option.

What "sublingual tirzepatide drops" typically means in practice

The preparations circulating under this description are usually compounded or otherwise unlicensed formulations, sometimes sold through social media channels or websites operating outside the regulated UK supply chain. They are not produced under MHRA oversight. Dose accuracy, sterility and stability in these preparations cannot be verified in the way they can for a medicine manufactured by Eli Lilly and supplied through the licensed UK wholesale chain.

This matters practically. If a preparation contains less active substance than labelled, a person using it may believe they are on treatment when the clinical effect is absent or negligible. If it contains more, or contains impurities, the risks are harder to predict. The MHRA has issued repeated public warnings about fake and unlicensed weight-loss products sold online; its guidance on reporting suspect sellers via Yellow Card is there precisely because these markets exist and cause harm.

It is also worth noting the legal position plainly: tirzepatide is a Prescription-Only Medicine. Supplying it in any form without a valid prescription from a registered prescriber is unlawful in the UK. Sellers offering tirzepatide preparations without that clinical assessment in place are operating outside the law, regardless of how the product is labelled or presented.

What a legitimate pathway to tirzepatide actually looks like

Licensed tirzepatide in the UK is Mounjaro, dispensed as a pre-filled KwikPen delivering a once-weekly subcutaneous dose. Treatment begins at 2.5mg (a dose chosen to help the body adjust before moving up) and is titrated by the prescriber, typically in four-week steps, toward the dose that achieves the right balance of effect and tolerability for that individual. You can read more about how the full treatment schedule works on our tirzepatide overview.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a named clinician, not an automated system. Identity is verified, weight is confirmed on a live video call, and the prescriber reviews the complete clinical picture before any decision is made. For those who have been wondering whether a sublingual preparation might be a gentler or easier alternative to injections, that's a question worth raising in a consultation, and our guide to tirzepatide dual action explains how the medicine works at a biological level so you can have a more informed conversation with your prescriber. Some people find the injection simpler than expected; injection technique and what to expect is something our prescribers walk through with every new patient.

If cost is part of what has drawn you toward unlicensed options, the context around Mounjaro pricing in the UK is worth reading, the market has changed significantly since Eli Lilly adjusted its list price in late 2025. Our treatment page shows what a prescription through nume includes in full, with no hidden charges layered on top.

The bigger picture: why this distinction protects you

People searching for sublingual tirzepatide are, in most cases, genuinely interested in effective weight management. That's a legitimate goal, and the frustration with waiting times, availability and cost in the licensed market is real. The concern with unlicensed preparations isn't bureaucratic caution for its own sake, it's that the entire evidence base showing tirzepatide works, and works safely, was built using a specific formulation at specific doses confirmed by blood-level testing. Deviate from that and you are, in clinical terms, in unknown territory, which is one reason our overview of Mounjaro or tirzepatide is a useful starting point for anyone trying to understand what they are actually being offered before committing to a course of treatment.

The NICE appraisal of tirzepatide (TA1026) considered the evidence available at the time of its December 2024 publication. That evidence, thousands of patients and 72 weeks of follow-up, told a consistent story about subcutaneous tirzepatide. No equivalent story exists for drops. If you're considering treatment, starting with a free clinical consultation is the route that keeps you in the part of the evidence base that actually exists. Our clinical team is available to answer questions before you commit to anything.